15 insiders reported 76 Form 4 transactions for BIOCRYST PHARMACEUTICALS INC (BCRX) over the past 18 months (most recent 2026-06-15). Recent activity: LEVIN ALAN G (Director) Buy 15,294 shares, MILANO VINCENT (Director) Buy 15,294 shares, Stonehouse Jon P (Director) Buy 15,294 shares, Galson Steven K (Director) Buy 15,294 shares, Frank Steven (Director) Buy 15,294 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-15 | LEVIN ALAN G | Director | Buy | 15,294 | $0 |
| 2026-06-15 | MILANO VINCENT | Director | Buy | 15,294 | $0 |
| 2026-06-15 | Stonehouse Jon P | Director | Buy | 15,294 | $0 |
| 2026-06-15 | Galson Steven K | Director | Buy | 15,294 | $0 |
| 2026-06-15 | Frank Steven | Director | Buy | 15,294 | $0 |
| 2026-06-15 | Milne Jill C. | Director | Buy | 15,294 | $0 |
| 2026-06-15 | SANDERS MACHELLE | Director | Buy | 15,294 | $0 |
| 2026-06-15 | HEGGIE THERESA | Director | Buy | 15,294 | $0 |
| 2026-06-15 | McKee Amy E | Director | Buy | 15,294 | $0 |
| 2026-06-02 | Milne Jill C. | Director | Buy | 1,262 | $11,244 |
| 2026-06-02 | Stonehouse Jon P | Director | Buy | 631 | $5,622 |
| 2026-06-02 | Frank Steven | Director | Buy | 1,262 | $11,244 |
| 2026-06-02 | MILANO VINCENT | Director | Buy | 1,122 | $9,997 |
| 2026-06-02 | McKee Amy E | Director | Buy | 631 | $5,622 |
| 2026-05-19 | McKee Amy E | Director | Sell | 11,180 | $100,285 |
| 2026-05-15 | Barnes Alane P | Chief Legal Officer | Buy | 62,500 | $315,000 |
| 2026-05-15 | Barnes Alane P | Chief Legal Officer | Sell | 62,500 | $596,250 |
| 2026-04-07 | Menon Sandeep | Chief R&D Officer | Buy | 205,150 | $0 |
| 2026-03-24 | HEGGIE THERESA | Director | Buy | 49,933 | $314,578 |
| 2026-03-24 | HEGGIE THERESA | Director | Sell | 49,933 | $504,823 |
| 2026-03-18 | Barnes Alane P | Chief Legal Officer | Buy | 150,000 | $826,500 |
| 2026-03-18 | Barnes Alane P | Chief Legal Officer | Sell | 150,000 | $1.4M |
| 2026-03-03 | Milne Jill C. | Director | Buy | 528 | $4,620 |
| 2026-03-03 | MILANO VINCENT | Director | Buy | 848 | $7,420 |
| 2026-03-03 | Frank Steven | Director | Buy | 1,285 | $11,244 |
Source: SEC Form 4 filings · as of 2026-06-15